Chronic lymphocytic leukemia patients with heterogeneously or fully methylated LPL promotor display longer time to treatment

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • Iben Daugaard
  • Dianna Hussmann
  • Louise Kristensen, Department of Clinical Pathology, Odense University Hospital, J. B. Winsløws Vej 15, Odense, 5000, Denmark.
  • ,
  • Thomas Kristensen, Department of Clinical Pathology, Odense University Hospital, J. B. Winsløws Vej 15, Odense, 5000, Denmark.
  • ,
  • Tina E Kjeldsen
  • Charlotte G Nyvold, Department of Haematology, Odense University Hospital, Sdr. Bouldvard 29, 5000 Odense C, Denmark.
  • ,
  • Thomas S Larsen, Department of Haematology, Odense University Hospital, Sdr. Bouldvard 29, 5000 Odense C, Denmark.
  • ,
  • Michael B Møller, Department of Clinical Pathology, Odense University Hospital, J. B. Winsløws Vej 15, Odense, 5000, Denmark.
  • ,
  • Lise Lotte Hansen
  • Tomasz K Wojdacz

Aim: We investigated whether DNA methylation regulates expression of LPL and PI3K complex genes in chronic lymphocytic leukemia (CLL) and evaluated the prognostic significance of LPL promoter methylation in CLL patients. Patients & methods: Methylation of LPL promoter was assessed in 112 patients using methylation-sensitive high-resolution melting (MS-HRM).Results: Patients with a fully or heterogeneously methylated LPL promoter had significantly longer median time to treatment (p < 0.001) and 75% lower (hazard ratio: 0.25; 95% CI: 0.15-0.42; p < 0.001) risk of requirement for treatment as opposed to patients with nonmethylated promoter. Multivariate modeling confirmed independent prognostic value of these findings. Conclusion: Chronic lymphocytic leukemia patients with a fully or heterogeneously methylated LPL gene promoter display indolent disease course and acquisition of heterogeneous methylation of LPL promoter is insufficient to induce gene expression.

Original languageEnglish
JournalEpigenomics
Volume10
Issue9
Pages (from-to)1155-1166
Number of pages12
ISSN1750-1911
DOIs
Publication statusPublished - Sep 2018

    Research areas

  • CLL, MS-HRM, biomarker, chronic lymphocytic leukemia, heterogeneous methylation, treatment

See relations at Aarhus University Citationformats

ID: 132732454